HealthCap

HealthCap is a specialized provider of venture capital within life sciences. HealthCap invests in innovative companies with focus on therapeutics.[1] HealthCap has invested in over 100 companies since inception and completed initial public offerings of more than 35 companies. HealthCap has offices in Stockholm, Oslo and Lausanne.

Private
Industry Private Equity and Venture Capital
Founded 1996
Headquarters Stockholm, Sweden, Oslo, Norway and Lausanne, Switzerland
Products Venture Capital
Total assets EUR 1 billion
Number of employees
~25 (2015)
Website www.healthcap.eu

History

The firm was founded in 1996 by Björn Odlander[2] and Peder Fredrikson[3] and the first fund was started the same year. As of 2012, HealthCap has established six funds. The first five funds have financed 91 companies, 35 of the companies were start-ups. The most recent fund, HealthCap VI, was established in the spring of 2011. In 2015, HealthCap had approximately 25 employees out of which eleven are partners. The team combines venture capital investing experience with competencies and work experiences from small as well as large companies across the health care industry, spanning disciplines of scientific research, drug development, clinical practice, investment banking, and industry management.

Specialties

HealthCap provides funding to innovative companies within the area of life sciences with a focus on therapeutics. Investments have to meet certain criteria such as fulfilment of important medical needs, high degree of innovation/transformational technologies and improvement in the economics of the health care sector.[4] The firm invests in a variety of instruments.

Assets under management

HealthCap has raised six main funds. HealthCap IV-VI are Delaware Limited Partnerships with a Swiss general partner. Investors in HealthCap funds include, among others, Skandia Life Insurance, the 4th and 6th Swedish National Pension Funds, The Kresge Foundation, Mayo Clinic, Northwestern University, University of Michigan, Vanderbilt University and Washington University.[5] In 2012 HealthCap had committed capital exceeding €900 million.[6][7]

Investments

HealthCap invests in companies developing disruptive technologies that hold the potential to change clinical practice. Over the years the portfolio companies have developed more than 20 pharmaceutical products and over 40 med-tech products to the market.[8] Many of these products, such as Firazyr®, Xofigo®, Tracleer®, are breakthrough therapies addressing life-threatening diseases. Examples of technologies financed by HealthCap are

External links

References

  1. "The investments". HealthCap.
  2. "Björn Odlander". Bloomberg Businessweek.
  3. "Peder Fredrikson". Bloomberg Businessweek.
  4. "The Investment Objective". HealthCap.
  5. "The Funds". HealthCap.
  6. "Company Overview of HealthCap". Bloomberg Businessweek.
  7. "Nordic HealthCap announces final close of its fourth biotech fund at $322m". The Alternative Assets Network.
  8. "HealthCap website". HealthCap.
  9. "Pulmonx Raises $32 Million for Launch of Emphysema Products". Reuters.
  10. "Algeta ASA Raises Euro 23 Million in Series A Round". CRM.
  11. "Medtronic Buying CoreValve for $700 Million+". Thomson Reuters.
  12. "Aerocrine: 3.32m EUR in new funds". Tornado Insider.
  13. "Oncos Therapeutics raises € 4 million from HealthCap to develop oncolytic viruses into cancer treatments". Oncos Therapeutics.
  14. "Investors up their stake in Tengion". The Business Journal.
  15. "Wilson Therapeutics" Life Science Sweden. April 17, 2014.
  16. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky, ML (2007). "Wilson's disease". Lancet 369 (9559): 397-408.
This article is issued from Wikipedia - version of the 8/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.